Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis

Background: Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system. Objectives: To estimate the clinical effectiveness of three interventions [everolimus (Afinitor®; Novartis International AG, Basel, Switzerland), lutetium-177 DO...

Full description

Bibliographic Details
Main Authors: Ruben Mujica-Mota, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Marcela Haasova, Jaime Peters, Stefano Lucherini, Juan Talens-Bou, Linda Long, David Sherriff, Mark Napier, John Ramage, Martin Hoyle
Format: Article
Language:English
Published: NIHR Journals Library 2018-09-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta22490

Internet

https://doi.org/10.3310/hta22490

Similar Items